Key result
Prophylactic use of apixaban (OR 0.46, p=0.001) and enoxaparin (OR 0.49, p=0.001) were associated with a significant decrease in mortality among COVID-19 inpatients.
Why the study?
Anticoagulation has been proposed to reduce mortality associated with prothrombotic parameters in COVID-19, but whether it improves survival and relates to disease severity required investigation.
Population
3,625 COVID-19+ inpatients
Comparison
Anticoagulation therapy chosen in the first 48 hours of hospitalization vs no anticoagulation
Design
Cohort study simulating an intention-to-treat clinical trial
Authors
Loading...
Supports prophylactic anticoagulation in COVID-19 inpatients; leaves open randomized confirmation of mortality benefit.
Cohort (n=3,625)
Odds Ratio: 0.46
p-value: p=0.001
Billett et al. (2020) conducted a cohort in COVID-19 (n=3,625). Anticoagulation therapy (apixaban, enoxaparin, heparin) vs. No anticoagulation / reference group was evaluated on Mortality (OR 0.46, p=0.001). Prophylactic use of apixaban (OR 0.46, p=0.001) and enoxaparin (OR 0.49, p=0.001) were associated with a significant decrease in mortality among COVID-19 inpatients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: